Seattle Genetics and Takeda's Millennium expand ADC technology deal
This article was originally published in Scrip
Executive Summary
Takeda's Millennium unit has paid Seattle Genetics an undisclosed fee to exercise an option to designate a second antigen target under the companies' existing collaboration on work regarding Seattle's antibody-drug conjugate (ADC) technology.